Quantcast
Home > Quotes > ZIOP
ZIOP

ZIOPHARM Oncology Inc Common Stock (ZIOP) Quote & Summary Data

$5.48
*  
0.17
3.01%
Get ZIOP Alerts
*Delayed - data as of Jul. 19, 2019  -  Find a broker to begin trading ZIOP now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
6.25
Today's High / Low
$ 5.71 / $ 5.455
Share Volume
1,058,864
50 Day Avg. Daily Volume
1,921,783
Previous Close
$ 5.65
52 Week High / Low
$ 6.30 / $ 1.56
Market Cap
889,921,827
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.92

Intraday Chart

Shares Traded

Share Volume:
1,058,864
50 Day Avg. Daily Volume:
1,921,783

P/E Ratio

P/E Ratio:
5.71
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ 0.96

Trading Range

The current last sale of $5.48 is 251.28% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.71 $ 6.30
 Low: $ 5.455 $ 1.56

ETFs with ZIOP as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
4.2% Loncar Cancer Immunotherapy ETF (CNCR) -1.00 (-4.45%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

ZIOP Company Description

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.

View Company Description as filed with the SEC ...  



Risk Grade

Where does ZIOP fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.64
Open Date:
Jul. 19, 2019
Close Price:
$ 5.48
Close Date:
Jul. 19, 2019


Consensus Recommendation

Analyst Info